Elios' customized cancer vaccine shows positive results

By The Science Advisory Board staff writers

Elios Therapeutics' personalized cancer vaccine shows a long-term survival benefit for patients with stage III or IV melanoma, according to final data from its clinical trial.

Three years after completing the vaccine series, 93% of high-risk melanoma patients remained alive, while 77% of patients who were given placebos survived, according to final data from a prospective, randomized, double-blind, placebo-controlled phase IIb clinical trial.

Elios' personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is made from a patient's tumor and blood. Every patient's tumor has a unique antigenic profile unlike any other, and dendritic cells found in the blood are the most potent antigen-presenting cells in the body.

Copyright © 2020 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking